Autotelic Bio to Initiate Phase 3 Clinical Trial for ATB-101, the World's 1st FDC for Hypertension and Diabetes
2022-07-04
Autotelic Bio Successfully Raised KRW 15.5 Billlion in Series B Investment
2022-03-28
ATB-101, a Fixed Dose Combination for Hypertension and Diabetes Got IND Approval for Phase 1 Clinical Trial
2021-03-02
Autotelic Bio Signed Agreement with Clinigen for Clinical Trials of Anti-cancer New Drug
2021-01-14
Autotelic Bio Raised Strategic Investment
2020-09-06
Autotelic Bio Raised Series A Investment
2020-01-07
